Prime Medicine PRME
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Jump To Section
$
About
Prime Medicine (PRME) Business Model and Operations Summary
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Key Insights
Prime Medicine (PRME) Stock Information & Key Business Metrics
Market Cap
$615.68 MillionAverage Daily Volume
2,910,357 Shares52-Week Range
$1.11-$6.94Free Cash Flow
-$158.74 MillionTotal Outstanding Shares
180.62 Million SharesFree Float
69.86 Million Shares (38.7% Outstanding)CEO
Allan ReineTotal Employees
146Current Dividend
$0.80 Per Share QuarterlyIPO Date
October 20, 2022Headquarters
60 First St., Cambridge, MA, 02141